Comparing Biomerica (BMRA) & Sartorius (SARTF)

Biomerica (NASDAQ:BMRA) and Sartorius (OTCMKTS:SARTF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Biomerica and Sartorius, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biomerica 0 0 1 0 3.00
Sartorius 1 0 0 0 1.00

Biomerica presently has a consensus target price of $7.50, suggesting a potential upside of 166.90%. Given Biomerica’s stronger consensus rating and higher possible upside, equities analysts plainly believe Biomerica is more favorable than Sartorius.

Institutional & Insider Ownership

1.5% of Biomerica shares are held by institutional investors. 26.8% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Biomerica and Sartorius’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biomerica -31.75% -41.73% -34.79%
Sartorius 9.09% 20.21% 7.10%

Valuation & Earnings

This table compares Biomerica and Sartorius’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biomerica $5.56 million 4.56 -$1.46 million ($0.17) -16.53
Sartorius $1.59 billion 3.17 $129.67 million N/A N/A

Sartorius has higher revenue and earnings than Biomerica.

Volatility and Risk

Biomerica has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Sartorius has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Biomerica Company Profile

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. It operates in Europe, the United States, Asia, South America, the Middle East, and internationally. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Sartorius Company Profile

There is no company description available for Sartorius AG.

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit